Baird Capital Co-Leads $21 Million Series B Financing for NeuMoDx Molecular Inc.

April 1, 2014

Baird Capital co-led a $21 million Series B financing in NeuMoDx Molecular Inc., a diagnostics company developing a new platform for high-efficiency, low-cost molecular testing. “Molecular diagnostic testing continues to be an attractive investment area for us and we look forward to working with Jeff, Sundu, and the experienced team they have assembled at NeuMoDx to provide the resources necessary for their continued growth,” said Nicole Walker, Director with Baird Capital. “NeuMoDx's vision of a fully-automated and low-cost testing solution for high volume molecular testing is the type of disruptive technology we look to invest in."

Read the full release.